Introduction

Abstract

This first issue of the relaunched journal includes five articles. The subject of these inter- and multi-disciplinary articles represents the journal’s goal to reach a wide audience. Sinha and colleagues showed how their molecular research is closely linked to a preclinical stage to prevent breast cancer cells entering dormancy, as well as to target established dormant breast cancer cells. The group previously showed that CDH2 is significant for gap junctional intercellular communication, which allowed the cancer cells to communicate with endogenous bone marrow cells resulting in cycling quiescence (1). The group reported on CDH2 as a therapeutic target for breast cancer (1). The paper in this issue cloned and analyzed the 5′ regulatory region of CDH2, and addressed how small non-coding microRNA could regulate CDH2 expression. This adds to additional method to target CDH2 to reverse and prevent breast cancer dormancy. The paper by Barboza and colleagues focused on lung carcinoma. Specifically, the group showed PDCD2 blunting the cycling of lung carcinoma by inhibiting the G0/G1 transition. The latter occurred by suppressed expression of cyclin D1.